20/20 Biolabs, Inc. - Common Stock (AIDX)
Investment Snapshot
- Piotroski F-Score 4/9 — moderate financial health
- Negative net margin (-182.8%) — currently unprofitable
- Revenue growing at 17% annually
20/20 Biolabs, Inc. - Common Stock (AIDX) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $19 million . Key value metrics: Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
20/20 Biolabs, Inc. - Common Stock — Fundamental Analysis Summary
StockPik's composite Value Score for AIDX is 42/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
AIDX reports a moderate gross margin of 29.6% and a negative operating margin of -162.9%.
AIDX shows revenue growing at 17% year-over-year, with earnings growing at 33%.